COVID-19 Coagulopathy

被引:0
|
作者
Rettew, Andrew [1 ]
Garrahy, Ian [1 ]
Rahimian, Shoja [1 ]
Brown, Rebecca [1 ]
Sangha, Navdeep [1 ]
机构
[1] Reading Hosp, Tower Hlth Syst, W Reading, PA 19611 USA
来源
LIFE-BASEL | 2024年 / 14卷 / 08期
关键词
coagulopathy; SARS-CoV-2; vasculopathy; OPEN-LABEL; THROMBOSIS; HOSPITALIZATION; ANTICOAGULATION; COMPLICATIONS; COAGULATION; MULTICENTER; CELLS; RISK;
D O I
10.3390/life14080953
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite being a primary respiratory illness, it is commonly complicated by systemic involvement of the vasculature leading to arterial and venous thrombosis. In this review, we will focus on the association between COVID-19 and thrombosis. We will highlight the pathophysiology of COVID-19 coagulopathy. The clinical manifestations of COVID-19 vasculopathy will be discussed with a focus on venous and arterial thromboembolic events. COVID-19 vasculopathy and disseminated intravascular coagulation (DIC) are distinguished within, as well as areas of controversy, such as "long COVID". Finally, the current professional guidelines on prevention and treatment of thrombosis associated with SARS-CoV-2 infection will be discussed.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Role of von Willebrand Factor in COVID-19 Associated Coagulopathy
    Mei, Zhen W.
    van Wijk, Xander M. R.
    Pham, Huy P.
    Marin, Maximo J.
    JOURNAL OF APPLIED LABORATORY MEDICINE, 2021, 6 (05): : 1305 - 1315
  • [22] COVID-19 Related Coagulopathy: What is Known Up to Now
    Pena, Ana Luisa Batista
    Oliveira, Rafael Arantes
    Severo, Renata Gomes
    Simoes e Silva, Ana Cristina
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (21) : 4207 - 4225
  • [23] Studying the coagulopathy of COVID-19
    Spyropoulos, Alex C.
    Bonaca, Marc P.
    LANCET, 2022, 399 (10320): : 118 - 119
  • [24] COVID-19: Coagulopathy and thrombosis
    Mezalek, Z. Tazi
    REVUE DE MEDECINE INTERNE, 2021, 42 (02): : 93 - 100
  • [25] Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia
    Costanzo, Luca
    Palumbo, Francesco Paolo
    Ardita, Giorgio
    Antignani, Pier Luigi
    Arosio, Enrico
    Failla, Giacomo
    JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS, 2020, 8 (05) : 711 - 716
  • [26] COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic
    Parks, Anna L.
    Auerbach, Andrew D.
    Schnipper, Jeffrey L.
    Anstey, James E.
    Sterken, David G.
    Hecht, Todd E. H.
    Fang, Margaret C.
    Vaughn, Valerie M.
    Dunn, Andrew S.
    Linker, Anne S.
    Hunt, Daniel P.
    Choi, Justin J.
    Brotman, Daniel J.
    Streiff, Michael B.
    Mattison, Melissa L. P.
    Pappas, Matthew A.
    Greysen, S. Ryan
    Hemsey, David F.
    Dapaah-Afriyie, Kwame
    Ahuja, Neera
    Collins, William J.
    Herzig, Shoshana J.
    Bhandari, Sanjay
    Schumacher, Eric R.
    Duggirala, Vijay S.
    O'Leary, Kevin J.
    Menard, Geraldine E.
    Lin, Michael Y.
    THROMBOSIS RESEARCH, 2020, 196 : 355 - 358
  • [27] COVID-19 coagulopathy: towards the understanding of pathogenesis
    Carrara, Davide
    ITALIAN JOURNAL OF MEDICINE, 2020, 14 (04) : 210 - 212
  • [28] Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy
    Seth, Ryan
    McKinnon, Thomas A. J.
    Zhang, X. Frank
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2022, 322 (01): : H87 - H93
  • [29] COVID-19 coagulopathy: is it disseminated intravascular coagulation?
    Levi, Marcel
    Iba, Toshiaki
    INTERNAL AND EMERGENCY MEDICINE, 2021, 16 (02) : 309 - 312
  • [30] COVID-19 coagulopathy: is it disseminated intravascular coagulation?
    Marcel Levi
    Toshiaki Iba
    Internal and Emergency Medicine, 2021, 16 : 309 - 312